Moffitt Cancer Center | Strategic Alliance Partners

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

Latest from Moffitt Cancer Center

Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer

July 11, 2022

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 04, 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

June 24, 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

New Programs Unlock Patient Access to Oncology Care

May 19, 2022

Developing a system with a patient-centric focus, investigators at Yale Cancer Center and Moffitt Cancer Center initiated pilot programs to offer patients better access to care following a diagnosis of cancer.

Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL

May 12, 2022

Bijal Shah, MD, MS, discusses the results of a phase 2 pilot study investigating CPX-351 in adults with high-risk relapsed/refractory acute lymphoblastic leukemia, as well as next steps for research in this patient population.

CG0070 Plus Nivolumab Under Investigation in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

May 04, 2022

The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.